pH-Responsive Artemisinin Derivatives and Lipid Nanoparticle Formulations Inhibit Growth of Breast Cancer Cells In Vitro and Induce Down-Regulation of HER Family Members

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Zhang, Yitong J ^a   Gallis, Byron ^a   Taya, Michio ^a   Wang, Shusheng ^a   Ho, Rodney J Y ^a   Sasaki, Tomikazu ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ DERIVATIVE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LIPOSOME; NANOPARTICLE; PIPERAZINE DERIVATIVE; SURVIVIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENDOSOME; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LIPOSOMAL DELIVERY; LYSOSOME; PH MEASUREMENT; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; ARTEMISININS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; LIPOSOMES; NANOPARTICLES; RECEPTOR, ERBB-2;

EID: 84875040713     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059086     Document Type: Article

References (65)

1. Hsu E, (2006) Reflections on the 'discovery' of the antimalarial qinghao. British J Clin Pharmaco 61: 666-670.
2. Miller LH, Su XZ, (2011) Artemisinin: Discovery from the Chinese Herbal Garden. Cell 146: 855-858.
3. White NJ, (2008) Qinghaosu (Artemisinin): The price of success. Science 320: 330-334.
4. Dondorp AM, Fanello CI, Hendriksen ICE, Gomes E, Seni A, et al. (2010) Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376: 1647-1657.
5. Taylor WRJ, White NJ, (2004) Antimalarial drug toxicity- A review. Drug Safety 27: 25-61.
6. Maude RJ, Plewes K, Faiz MA, Hanson J, Charunwatthana P, et al. (2009) Does Artesunate Prolong the Electrocardiograph QT Interval in Patients with Severe Malaria? Am J Trop Med Hyg 80: 126-132.
7. Posner GH, Paik I-H, Chang W, Borstnik K, Sinishtaj S, et al. (2007) Malaria-infected mice are cured by a single dose of novel artemisinin derivatives. J Med Chem 50: 2516-2519.
8. Carter MD, Hoang AN, Wright DW, (2009) Hemozoin: A paradigm for biominerals in disease. Wiley Encyclopedia of Chemical Biology 2: 250-260.
9. Meunier B, Robert A, (2010) Heme as Trigger and Target for Trioxane-Containing Antimalarial Drugs. Acc Chem Res 43: 1444-1451.
10. Weissbuch I, Leiserowitz L, (2008) Interplay Between Malaria, Crystalline Hemozoin Formation, and Antimalarial Drug Action and Design. Chem Rev 108: 4899-4914.
11. Karin M, Mintz B, (1981) Receptor-Mediated Endocytosis of Transferrin in Developmentally Totipotent Mouse Treatocarcinoma Stem-Cells. J Biol Chem 256: 3245-3252.
12. Das-Gupta A, Patil J, Shah V, (1996) Transferrin Receptor Expression by Blast Cells in Acute Lymphoblastic Leukemia Correlates with White Cell Count and Immunophenotype. Indian J Med Res 104: 226-233.
13. May WS, Cuatrecasas P, (1985) TRANSFERRIN RECEPTOR- ITS BIOLOGICAL SIGNIFICANCE. J Membrane Biol 88: 205-215.
14. Raaf H, Jacobsen D, Savon S, Green R, (1993) Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast. Am J Clin Pathol 99: 232-237.
15. Reizenstein P, (1991) IRON, FREE-RADICALS AND CANCER. Med Oncol Tumor Pharmacother 8: 229-233.
16. Chaturvedi D, Goswami A, Saikia PP, Barua NC, Rao PG, (2010) Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chem Soc Rev 39: 435-454.
17. Gravett AM, Liu WM, Krishna S, Chan WC, Haynes RK, et al. (2011) In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemoth Pharm 67: 569-577.
18. He R, Mott BT, Rosenthal AS, Genna DT, Posner GH, et al. (2011) An Artemisinin-Derived Dimer Has Highly Potent Anti-Cytomegalovirus (CMV) and Anti-Cancer Activities. Plos One 6.
19. Hindley S, Ward SA, Storr RC, Searle NL, Bray PG, et al. (2002) Mechanism-based design of parasite-targeted artemisinin derivatives: Synthesis and antimalarial activity of new diamine containing analogues. J Med Chem 45: 1052-1063.
20. Ji Y, Zhang YC, Pei LB, Shi LL, Yan JL, et al. (2011) Anti-tumor effects of dihydroartemisinin on human osteosarcoma. Mol Cell Biochem 351: 99-108.
21. Jung M, Lee S, Ham J, Lee K, Kim H, et al. (2003) Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer. J Med Chem 46: 987-994.
22. Stockwin LH, Han BN, Yu SX, Hollingshead MG, ElSohly MA, et al. (2009) Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer 125: 1266-1275.
23. Tan WF, Shen F, Luo XJ, Su CQ, Qiu ZQ, et al. (2011) Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine 18: 158-162.
24. Yang XL, Liu D, Wang W, Qu L, Jing YK, et al. (2009) Design, Synthesis and Antiproliferative Activities of Artemisinin Derivatives Containing a Substituted Piperazine. Letters in Drug Design & Discovery 6: 595-598.
25. Singh NP, Lai H, (2001) Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70: 49-56.
26. Posner GH, Northrop J, Paik IH, Borstnik K, Dolan P, et al. (2002) New chemical and biological aspects of artemisinin-derived trioxane dimers. Bioorgan Med Chem 10: 227-232.
27. Posner GH, Paik IH, Sur S, McRiner AJ, Borstnik K, et al. (2003) Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J Med Chem 46: 1060-1065.
28. Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, et al. (2004) Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem 47: 1299-1301.
29. Nakase I, Gallis B, Takatani-Nakase T, Oh S, Lacoste E, et al. (2009) Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett 274: 290-298.
30. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, et al. (2010) Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs 21: 423-432.
31. Firestone GL, Sundar SN, (2009) Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 11.
32. Gao N, Budhraja A, Cheng S, Liu EH, Huang C, et al. (2011) Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis 16: 511-523.
33. Galal AM, Gul W, Slade D, Ross SA, Feng S, et al. (2009) Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. Bioorgan Med Chem 17: 741-751.
34. Singh NP, Lai HC, Park JS, Gerhardt TE, Kim BJ, et al. (2011) Effects of Artemisinin Dimers on Rat Breast Cancer Cells In Vitro and In Vivo. Anticancer Res 31: 4111-4114.
35. Augustijns P, Dhulst A, VanDaele J, Kinget R, (1996) Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells. J Pharm Sci 85: 577-579.
36. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, et al. (2011) Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malaria J 10: 17.
37. Kreuter J, (1991) NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS. Journal of Control Release 16: 169-176.
38. (1999) Liposomes: Rational Design. New York, USA: Marcel Dekker, Inc. 451 p.
39. Allen TM, Cullis PR, (2004) Drug delivery systems: Entering the mainstream. Science 303: 1818-1822.
40. (1998) Medical Applications of Liposomes. The Netherlands: Elsevier Science B.V. 779 p.
41. Hashim AI, Zhang XM, Wojtkowiak JW, Martinez GV, Gillies RJ, (2011) Imaging pH and metastasis. Nmr Biomed 24: 582-591.
42. Schindler M, Grabski S, Hoff E, Simon SM, (1996) Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry 35: 2811-2817.
43. Martinez GV, Zhang X, García-Martín ML, Morse DL, Woods M, et al. (2011) Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents. NMR Biomed 24: 1380-1391.
44. Kinman L, Brodie SJ, Tsai CC, Bui T, Larsen K, et al. (2003) Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: A proof of concept study in HIV-2(287)-infected macaques. Jaids-J Acq Imm Def 34: 387-397.
45. Choi SU, Bui T, Ho RJY, (2008) pH-dependent interactions of indinavir and lipids in nanoparticlies and their ability to entrap a solute. J Pharm Sci 97: 931-943.
46. Kinman L, Bui T, Larsen K, Tsai CC, Anderson D, et al. (2006) Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. Jaids-J Acq Imm Def 42: 155-161.
47. Xia WL, Bisi J, Strum J, Liu LH, Carrick K, et al. (2006) Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 66: 1640-1647.
48. Velasco-Velazquez MA, Li Z, Casimiro M, Loro E, Homsi N, et al. (2011) Examining the role of cyclin D1 in breast cancer. Future Oncol 7: 753-765.
49. de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC, (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin 137: 183-192.
50. Chakraborti AK, Rudrawar S, Kondaskar A, (2004) Lithium bromide, an inexpensive and efficient catalyst for opening of epoxide rings by amines at room temperature under solvent-free condition. Eur J Org Chem 17: 3597-3600.
51. Huotari J, Helenius A, (2011) Endosome maturation. Embo J 30: 3481-3500.
52. Mu D, Chen W, Yu B, Zhang C, Zhang Y, et al. (2007) Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. Methods Findings Exp Clin 29: 33-38.
53. Li L-N, Zhang H-D, Yuan S-J, Tian Z-Y, Wang L, et al. (2007) Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int J Cancer 121: 1360-1365.
54. Yamamoto H, Ngan CY, Monden M, (2008) Cancer cells survive with survivin. Cancer Sci 99: 1709-1714.
55. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, et al. (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67: 8014-8021.
56. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, et al. (2008) Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. J Clin Oncol 26: 5198-5203.
57. Masamha CP, Benbrook DM, (2009) Cyclin D1 Degradation Is Sufficient to Induce G(1) Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer Cells. Cancer Res 69: 6565-6572.
58. Shan J, Zhao W, Gu W, (2009) Suppression of Cancer Cell Growth by Promoting Cyclin D1 Degradation. Mol Cell 36: 469-476.
59. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human-Breast Cancer- Correlation of Relapse and Survival With Amplification of the HER-2 Neu Oncogene. Science 235: 177-182.
60. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, et al. (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. P Natl A Sci USA 108: 5021-5026.
61. Cook RS, Garrett JT, Sanchez V, Stanford JC, Young C, et al. (2011) ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis. Cancer Res 71: 3941-3951.
62. Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, et al. (2002) AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21: 3532-3540.
63. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, et al. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. P Natl A Sci USA 100: 8933-8938.
64. Amin DN, Campbell MR, Moasser MM, (2010) The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 21: 944-960.
65. Garrett JT, Arteaga CL, (2011) Resistance to HER2-directed antibodies and tyrosine kinase inhibitors. Cancer Biol Ther 11: 793-800.